- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04552353
Evaluate Bioequivalence of Voriconazole(200mg/Vial) .
September 11, 2020 updated by: Yung Shin Pharm. Ind. Co., Ltd.
A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Voriconazole(200mg/Vial) After Intravenous Infusion of 200mg Voriconazole in Healthy Volunteers Under Fasting Conditions.
A Randomized, Single-dose, Two-way Crossover Study to Evaluate Bioequivalence of Two Formulations of Voriconazole(200mg/Vial) After Intravenous Infusion of 200mg Voriconazole in Healthy Volunteers Under Fasting Conditions.
Study Overview
Study Type
Interventional
Enrollment (Actual)
14
Phase
- Phase 4
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Taichung, Taiwan
- Taichung Veterans General Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years to 45 years (Adult)
Accepts Healthy Volunteers
Yes
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy adult male or female subjects between 20-45 years of age (inclusive) at the screening visit.
Body weight within 80-120% of ideal body weight but not less than 45kg at the screening visit.
- Ideal body weight (kg) = [height (cm) - 80] ´ 0.7 for male subjects
- Ideal body weight (kg) = [height (cm) - 70] ´ 0.6 for female subjects
Acceptable medical history and physical examination including:
- no particular clinically significant abnormalities in Electrocardiogram(ECG) results within six months prior to Period I dosing.
- no particular clinical significance in general disease history within two months prior to Period I dosing.
- Acceptable biochemistry determinations (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes ASpartate aminoTransferase (AST), ALanine aminoTransferase (ALT), Gamma-Glutamyl-Transpeptidase (g-GT), alkaline phosphatase, total bilirubin, albumin, glucose, BUN, uric acid, creatinine, total cholesterol, and triglyceride (TG).
- Acceptable hematology (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes hemoglobin, hematocrit, red blood cell count, white blood cell count with differentials and platelets.
- Acceptable urinalysis (within normal limits or considered by the investigator or physician to be of no clinical significance) within two months prior to Period I dosing, which includes pH, blood, glucose, ketones, bilirubin and protein.
- Female of childbearing potential practicing an acceptable method of birth control for the duration of the study.
- Have signed the written informed consent to participate in this study.
Exclusion Criteria:
- A clinically significant disorder involving the cardiovascular, respiratory, hepatic, renal, gastrointestinal, immunologic, hematologic, endocrine or neurologic system(s) or psychiatric disease (as determined by the investigator).
- A clinically significant illness or surgery within four weeks prior to Period I dosing (as determined by the investigator).
- History of gastrointestinal obstruction, inflammatory bowel disease, gallbladder disease, pancreas disorder over last two years or history of gastrointestinal tract surgery over last five years.
- History of kidney disease or urination problem over last two years deemed by the investigator to be clinically significant.
- Known or suspected history of drug abuse within lifetime as judged by the investigator.
- History of alcohol addiction or abuse within last five years as judged by the investigator.
- History of allergic response(s) to voriconazole, any other drugs analogous to voriconazole, or any antibiotics.
- Evidence of chronic or acute infectious diseases.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Non-Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Vaway Lyo-Injection
Voriconazole, 200 mg/vial
|
Drug: Voriconazole.
Pharmacokinetic study under fasting conditions
Other Names:
|
Active Comparator: Vfend Lyo-Injection
Voriconazole, 200 mg/vial
|
Drug: Voriconazole.
Pharmacokinetic study under fasting conditions
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Peak concentration (Cmax)
Time Frame: 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
The 90% confidence intervals of the geometric mean ratio (test/reference) for all parameters of voriconazole should fall within the range of 80.00% and 125.00%.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
Time to reach peak concentration (Tmax)
Time Frame: 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
The 90% confidence intervals of the geometric mean ratio (test/reference) for all parameters of voriconazole should fall within the range of 80.00% and 125.00%.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
Area under the plasma concentration-time curve from time zero to time of last quantifiable concentration (AUC 0-t)
Time Frame: 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
The 90% confidence intervals of the geometric mean ratio (test/reference) for all parameters of voriconazole should fall within the range of 80.00% and 125.00%.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
Area under the plasma concentration-time curve from time zero to infinity (AUC 0-∞)
Time Frame: 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
The 90% confidence intervals of the geometric mean ratio (test/reference) for all parameters of voriconazole should fall within the range of 80.00% and 125.00%.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
Elimination rate constant (入z)
Time Frame: 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
The 90% confidence intervals of the geometric mean ratio (test/reference) for all parameters of voriconazole should fall within the range of 80.00% and 125.00%.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
Terminal elimination half-life (t 1/2)
Time Frame: 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
The 90% confidence intervals of the geometric mean ratio (test/reference) for all parameters of voriconazole should fall within the range of 80.00% and 125.00%.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
Ratio of AUC 0-t to AUC 0-∞
Time Frame: 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
The 90% confidence intervals of the geometric mean ratio (test/reference) for all parameters of voriconazole should fall within the range of 80.00% and 125.00%.
|
0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Adverse events and incidences
Time Frame: 0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
Any symptom, sign or significant abnormal laboratory finding whether observed or reported during the course of the study will be reported as an adverse event (AE) whether or not it has causative relationship with the drug
|
0 (pre-dose), 0.5, 1.0, 1.5, 2.0, 2.5, 3.0, 3.5, 4.0, 4.5, 5.0, 6.0, 7.0, 8.0, 10, 12, 24, and 36 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
June 13, 2020
Primary Completion (Actual)
June 21, 2020
Study Completion (Actual)
June 21, 2020
Study Registration Dates
First Submitted
September 11, 2020
First Submitted That Met QC Criteria
September 11, 2020
First Posted (Actual)
September 17, 2020
Study Record Updates
Last Update Posted (Actual)
September 17, 2020
Last Update Submitted That Met QC Criteria
September 11, 2020
Last Verified
September 1, 2020
More Information
Terms related to this study
Other Study ID Numbers
- YSP-RKH3003-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Antimycotic for Systematic Use
-
University of FloridaJohns Hopkins University; National Institutes of Health (NIH)CompletedYouths At-risk for Drug Use/AbuseUnited States
-
Restor3DTerminatedClinical Condition Included in the Approved Indications For Use for the Conformis Hip SystemUnited States
-
B. Braun Melsungen AGCompletedIntravenous Access According to Instructions For UseGermany
-
Johns Hopkins UniversityNational Institute on Drug Abuse (NIDA)CompletedCaffeine Use Disorder (DSM-5 Condition for Further Study)United States
-
Toshiba America Medical Systems, Inc.UnknownConfirm PCA-9000A PET/CT System is Effective for Its Intended UseUnited States
-
Shaare Zedek Medical CenterActive, not recruitingUse of GnRH Agonist Alone for Luteal Phase Support in Fresh IVF CyclesIsrael
-
Nexstim LtdEnrolling by invitationUsability of the Graphical User Interface of the Device for Its Intended UseFinland
-
University of California, BerkeleyProcter and GambleUnknownConsumer Willingness to Pay for POU Products | Consumer Preferences and Use of POU ProductsKenya
-
Meir Medical CenterUnknownCurcumin Use for Gynecological ConditionsIsrael
-
Bispebjerg HospitalCompletedInvestigate the Potential Network Limitations | Validate the Technology for Later Clinical Use | Evaluate System Integration of EndoAlphaDenmark
Clinical Trials on Vaway
-
Yung Shin Pharm. Ind. Co., Ltd.Taichung Veterans General HospitalCompletedFungus Infection